We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00327639
Recruitment Status : Unknown
Verified July 2005 by University Health Network, Toronto.
Recruitment status was:  Recruiting
First Posted : May 18, 2006
Last Update Posted : May 18, 2006
Sponsor:
Information provided by:

Study Description
Brief Summary:
Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years, with improvements in transfusion therapy and introduction of iron chelation therapy. Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life, with fertility and childbearing becoming important issues. Data regarding this important topic remain limited, without clear data regarding iron control including serial assessment of hepatic iron concentration, the need for assistance in becoming pregnant, and use of iron chelating agents during pregnancy. As the life expectancy increases and overall health improves in thalassemia, clear data on fertility, pregnancy complications, and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care, quality of life, and patient expectations.

Condition or disease
Thalassemia Fertility Pregnancy

Study Design

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto
Study Start Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Thalassemia, thalassemia intermedia or E-thalassemia patients in Toronto
  • Subject has attempted conception

Exclusion Criteria:

  • Subject has any other form of blood disease
  • Subject has not attempted conception
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327639


Contacts
Contact: Anthony Apostoli, B.Sc. 416-340-4800 ext 6069 Anthony.Apostoli@uhn.on.ca

Locations
Canada, Ontario
University Health Network, Toronto General Hospital Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contact: Valerie M Joseph    416-340-4800 ext 6507    Valerie.Joseph@uhn.on.ca   
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Nancy F Olivieri, MD University Health Network, Toronto General Hospital
More Information

ClinicalTrials.gov Identifier: NCT00327639     History of Changes
Other Study ID Numbers: 00000
First Posted: May 18, 2006    Key Record Dates
Last Update Posted: May 18, 2006
Last Verified: July 2005

Additional relevant MeSH terms:
Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn